QLT091001
QLT091001 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers
Clinical Trials (5)
Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5